Phase I/II trial of oncolytic reovirus (Reolysin) in combination with carboplatin/paclitaxel in patients (pts) with advanced solid cancers

被引：0
|
作者：
Karapanagiotou, E. [1 ,2 ,3 ,4 ]
Pandha, H. S. [1 ,2 ,3 ,4 ]
Hall, G. [1 ,2 ,3 ,4 ]
Chester, J. [1 ,2 ,3 ,4 ]
Melcher, A. [1 ,2 ,3 ,4 ]
Coffey, M. [1 ,2 ,3 ,4 ]
de Bono, J. [1 ,2 ,3 ,4 ]
Gore, M. E. [1 ,2 ,3 ,4 ]
Nutting, C. M. [1 ,2 ,3 ,4 ]
Harrington, K. J. [1 ,2 ,3 ,4 ]
机构：
[1] Royal Marsden Hosp, NHS Fdn Trust, London SW3 6JJ, England
[2] Univ Surrey, Guildford GU2 5XH, Surrey, England
[3] Leeds Inst Mol Med, Leeds, W Yorkshire, England
[4] Oncolyt Biotech Inc, Calgary, AB, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14519
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Paclitaxel and carboplatin in combination with gemcitabine: A phase I-II trial in patients with advanced non-small-cell lung cancer
    Favaretto, A
    Ceresoli, GL
    Paccagnella, A
    Barbieri, F
    Bearz, A
    Ghiotto, C
    Oniga, F
    Schiavon, S
    Frustaci, S
    Villa, E
    ANNALS OF ONCOLOGY, 2000, 11 (11) : 1421 - 1426
  • [42] Gemcitabine and carboplatin combination in advanced solid tumors: A phase I trial.
    Tassinari, D
    Pasini, G
    Arcangeli, V
    Panzini, I
    Drudi, G
    Gianni, L
    Oliverio, G
    Sartori, S
    Fochessati, F
    ANNALS OF ONCOLOGY, 2000, 11 : 141 - 141
  • [43] A Phase I Study to Evaluate Systemic Wild-type Reovirus (REOLYSIN)® in Combination With Docetaxel in Patients With Advanced Malignancies
    Comins, Charlie
    Spicer, James
    Protheroe, Andrew
    Mukherji, D.
    Coffey, Matt
    Thompson, Brad
    Harrington, Kevin
    Pandha, Hardev
    JOURNAL OF IMMUNOTHERAPY, 2008, 31 (09) : 951 - 951
  • [44] Oncolytic Reovirus in Combination with Paclitaxel/Carboplatin in NSCLC Patients with Ras Activated Malignancies, Long Term Results
    Villalona, Miguel
    Lam, Elaine
    Otterson, Gregory
    Zhao, Weqiang
    Timmons, Matthew
    Subramaniam, Deepa
    Hade, Erin
    Bertino, Erin
    Chao, Bo
    Selvaggi, Giovanni
    Knopp, Michael
    Gill, George M.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S372 - S372
  • [45] Results of a phase II study to evaluate the biological effects of intratumoral (ITu) reolysin in combination with low dose radiotherapy (RT) in patients (Pts) with advanced cancers
    Saunders, M.
    Anthoney, A.
    Coffey, M.
    Mettinger, K.
    Thompson, B.
    Melcher, A.
    Nutting, C. M.
    Harrington, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [46] Phase I trial of paclitaxel/carboplatin in advanced carcinoma of the urothelium
    Vaughn, DJ
    Malkowicz, SB
    Zoltick, B
    Ramchandani, P
    Tonkonow, B
    Armstead, B
    Wein, A
    SEMINARS IN ONCOLOGY, 1997, 24 (01) : S47 - S50
  • [47] REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors
    Morris, Don G.
    Feng, Xiaolan
    DiFrancesco, Lisa M.
    Fonseca, Kevin
    Forsyth, Peter A.
    Paterson, Alexander H.
    Coffey, Matt C.
    Thompson, Brad
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (03) : 696 - 706
  • [48] REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors
    Don G. Morris
    Xiaolan Feng
    Lisa M. DiFrancesco
    Kevin Fonseca
    Peter A Forsyth
    Alexander H. Paterson
    Matt C. Coffey
    Brad Thompson
    Investigational New Drugs, 2013, 31 : 696 - 706
  • [49] Everolimus (RAD001C) in combination with carboplatin (C) and paclitaxel (P) as first line treatment for patients (pts) with advanced NSCLC: a phase I trial
    Papadimitrakopoulou, Vassiliki A.
    Malik, Shakun
    Brown, Michael P.
    Mitchell, Paul
    Thomas, Michael
    Mills, Glenn
    Pylaevanaeinen, Ilona
    Lilla, Di Scala
    Kunz, Tiffany
    Dimitrijevic, Sasa
    DeLeo, Jeffrey J.
    Korfee, Soenke
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S446 - S447
  • [50] A phase 1 study of selinexor (S) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced ovarian (OC) or endometrial cancers (EC)
    Makker, V.
    Boucicaut, N.
    Cadoo, K. A.
    Grisham, R.
    Hyman, D. M.
    O'Cearbhail, R.
    Charen, A. Snyder
    Tew, W.
    Martin, M.
    Aghajanian, C.
    ANNALS OF ONCOLOGY, 2017, 28
12345